# Chemed share price today (Chemed Corporation, CHE)

> Chemed Corporation's results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 24% of past readings. CHE · Healthcare · Medical Care Facilities · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/che

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $533.65 (+23.7% in a year)
- P/E: 25.5× (lower than 76% of the last 4.6 years)
- Revenue (Jun 2026): $673 M (+8.8% on a year ago)
- Profit (Jun 2026): $67.7 M (+29.0% on a year ago)
- Operating margin: 13.2% (+2.2 points on a year ago)
- ROE: 27%, FY25
- ROIC: 24.6%, against a 6.6% cost of capital: +18.0 points

The main question: the share price moved +23.7% in a year while yearly earnings per share moved −7.8%. The difference came from the market paying a higher multiple. ## What is the Chemed share price today? Chemed Corporation's share price was $533.65 at the close on 3 November 2026. It has been rising for 4 weeks. That is 15.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $369 and $553, and at that close it sat 90% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 5 weeks running. Over the last 10 years the share price moved +288% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 2 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Chemed pay? Chemed Corporation paid $2.40 per share over the last four reported quarters. The most recent declaration was $0.60 for Jun 2026. At today's price of $533.65 that is a yield of 0.45%, based on dividends already paid, not a forecast. ## Which stock lists is Chemed on? Chemed is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Chemed profitable? Chemed Corporation earned $67.7 M of net profit in the Jun 2026 quarter, +29.0% on the same quarter a year earlier. Full-year FY25 profit was $265 M. Over 4 years profit has grown −0.3% a year on average. That is 10.1% of the quarter's revenue. The same quarter a year earlier earned $52.5 M. For the full year, FY25 profit was $265 M (−12.2% on the year before). Why profit moved: revenue changed +8.8% on a year earlier and the margin moved +2.2 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −2.2% and revenue +3.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Chemed make, and is it growing? Chemed Corporation reported $673 M of revenue in the Jun 2026 quarter, +8.8% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 4.3% a year on average. The last full year, FY25, came in at $2.5 B. The last four reported quarters add to $2.6 B. FY25 revenue was $2.5 B, +4.1% on the year before. Recent pace: the last four quarters grew +3.4% on average, against 4.3% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.3%, against +5.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −5.3%, against −4.4% a year (stabilising). ## How much of every $100 of sales does Chemed keep? Chemed Corporation's operating margin was 13.2% in the Jun 2026 quarter, 2.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 13.6% and 16.3%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed +2.2 percentage points on the year while gross margin changed +3.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Chemed's profit turning into cash? Over the last 3 years, 135% of Chemed Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $388 M of operating cash against $265 M of profit. After $62.8 M of spending on assets, $325 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Chemed's cash go? Chemed Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $169 M on assets over the last 3 years. Averaged over those years that is 2.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $169 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Chemed's P/E ratio, and how does it compare with its own history? Chemed Corporation's P/E is 25.5×, near the low end of its own history: it has been lower only 24% of the time. Its usual P/E (the middle reading) is 28.2×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −7.8% while the price moved +23.7%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved −3.1% a year; about +7.2% a year came from earnings growth and about −10.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Chemed business getting better or worse? Chemed Corporation's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 26.1%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Chemed earn on its capital? Chemed Corporation earned a ROE of 27% in FY25. That is up from a low of 25% in FY23. Its return on capital used (ROIC) is 18.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 10.5% net margin and 1.64× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 10.5% net margin × 1.64× asset turnover × 1.57× leverage (assets divided by equity) ≈ 27.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 24.6% − 6.6% = +18.0 percentage points. The 6.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Chemed have too much debt? Chemed Corporation has total debt of $295 M against shareholder equity of $831 M as of Jun 2026, so its debt is 0.35× its equity. Year by year, that ratio went from 0.52 in FY21 to 0.15 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Chemed shareholding pattern? 5.8% of Chemed Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Chemed from balance-sheet trouble? For Chemed Corporation, the Z-score is 9.16. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 9.16 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Chemed rank in its industry? 49.5 out of 100, rank 16 of 30 in Medical Care Facilities, with 81% of the evidence available. Chemed Corporation scores 49.5 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 16. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 17.4 + 19.7 + 5 + 7.4 = 49.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Chemed compared with? Chemed ranks 16 of 30 Medical Care Facilities companies on the 4-Factor Sector Score, with 49.5 out of 100. 1. [Concentra Group Holdings Parent, Inc.](https://www.sectoralpha.in/us/stocks/con) CON · leader · Most evidence points up · 81% evidence 71.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 14% · Profit 32.6% · Operating margin change 2.3 points · 83% evidence Capital efficiency 16.6/25 · ROCE 14.5% · Operating margin 19.3% · 76% evidence Valuation 13.0/20 · P/E 19.5× · PEG 0.65 · 65% evidence Relative strength 17.3/20 · Lead over its industry 18.3% · Lead over S&P 500 41.8% · 1 year 107.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.4 + 16.6 + 13 + 17.3 = 71.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Tenet Healthcare Corporation](https://www.sectoralpha.in/us/stocks/thc) THC · losing its lead · Evidence leans up · 81% evidence 64.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 5.4% · Profit 32.4% · Operating margin change 2.1 points · 83% evidence Capital efficiency 17.1/25 · ROCE 15% · Operating margin 18.2% · 76% evidence Valuation 15.3/20 · P/E 7.2× · PEG 0.35 · 65% evidence Relative strength 11.1/20 · Lead over its industry -3.8% · Lead over S&P 500 16.9% · 1 year 29.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21 + 17.1 + 15.3 + 11.1 = 64.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [AMN Healthcare Services, Inc.](https://www.sectoralpha.in/us/stocks/amn) AMN · breaking out · Evidence leans up · 64% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 23.9% · Profit n/a · Operating margin change 3.4 points · 62% evidence Capital efficiency 9.1/25 · ROCE 10.1% · Operating margin 4% · 76% evidence Valuation 10.4/20 · P/E 12× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.8% · Lead over S&P 500 63.5% · 1 year 153.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.3 + 9.1 + 10.4 + 19.6 = 64.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Pediatrix Medical Group, Inc.](https://www.sectoralpha.in/us/stocks/md) MD · turning · Evidence leans up · 81% evidence 62.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 0.6% · Profit 61.5% · Operating margin change -0.2 points · 83% evidence Capital efficiency 14.6/25 · ROCE 14.8% · Operating margin 13.4% · 76% evidence Valuation 13.1/20 · P/E 11.6× · PEG 0.8 · 65% evidence Relative strength 15.2/20 · Lead over its industry 1.2% · Lead over S&P 500 23% · 1 year 39.5% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.4 + 14.6 + 13.1 + 15.2 = 62.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Healthcare Services Group, Inc.](https://www.sectoralpha.in/us/stocks/hcsg) HCSG · turning · Evidence leans up · 85% evidence 61.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 4% · Profit 100% · Operating margin change -3.2 points · 95% evidence Capital efficiency 14.5/25 · ROCE 17.7% · Operating margin 6.7% · 76% evidence Valuation 14.4/20 · P/E 13.4× · PEG 0.43 · 65% evidence Relative strength 12.6/20 · Lead over its industry -4.8% · Lead over S&P 500 15.9% · 1 year 48.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 14.4 + 12.6 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Encompass Health Corporation](https://www.sectoralpha.in/us/stocks/ehc) EHC · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.5% · Profit 20.2% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.1/25 · ROCE 17% · Operating margin 18.1% · 76% evidence Valuation 12.4/20 · P/E 16.2× · PEG 0.8 · 65% evidence Relative strength 12.9/20 · Lead over its industry -4.8% · Lead over S&P 500 16.2% · 1 year 16.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 18.1 + 12.4 + 12.9 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Nutex Health Inc.](https://www.sectoralpha.in/us/stocks/nutx) NUTX · leader · Evidence leans up · 64% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 6.8% · Profit 100% · Operating margin change 44 points · 62% evidence Capital efficiency 18.6/25 · ROCE 56.8% · Operating margin 57.8% · 76% evidence Valuation 10.9/20 · P/E 6.5× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -5.5% · Lead over S&P 500 14.2% · 1 year 56.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.5 + 18.6 + 10.9 + 8.3 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aveanna Healthcare Holdings Inc.](https://www.sectoralpha.in/us/stocks/avah) AVAH · leader · Too little evidence to rank firmly · 58% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.3/35 · Revenue n/a · Profit n/a · Operating margin change 1.6 points · 45% evidence Capital efficiency 15.3/25 · ROCE 17.7% · Operating margin 12.6% · 76% evidence Valuation 10.7/20 · P/E 7.2× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 14.4% · Lead over S&P 500 37.9% · 1 year 51.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 15.3 + 15.3 + 10.7 + 18.2 = 59.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Addus HomeCare Corporation](https://www.sectoralpha.in/us/stocks/adus) ADUS · turning · Evidence leans up · 81% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 15.9% · Profit 27.7% · Operating margin change 0.3 points · 83% evidence Capital efficiency 12.9/25 · ROCE 11.4% · Operating margin 9.7% · 76% evidence Valuation 13.0/20 · P/E 17.4× · PEG 0.67 · 65% evidence Relative strength 10.7/20 · Lead over its industry -8.5% · Lead over S&P 500 11.9% · 1 year 11.9% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21 + 12.9 + 13 + 10.7 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [HCA Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/hca) HCA · breaking out · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 7.3% · Profit 14.6% · Operating margin change -0.7 points · 83% evidence Capital efficiency 19.9/25 · ROCE 26.3% · Operating margin 15.2% · 76% evidence Valuation 14.3/20 · P/E 12.6× · PEG 0.49 · 65% evidence Relative strength 7.2/20 · Lead over its industry -21.2% · Lead over S&P 500 -2.7% · 1 year -2.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 19.9 + 14.3 + 7.2 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) UHS · losing its lead · Evidence leans up · 81% evidence 56.3 out of 100 Growth Capital Valuation Relative
12. [LifeStance Health Group, Inc.](https://www.sectoralpha.in/us/stocks/lfst) LFST · turning · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative
13. [National HealthCare Corporation](https://www.sectoralpha.in/us/stocks/nhc) NHC · quiet · Evidence leans up · 81% evidence 54.0 out of 100 Growth Capital Valuation Relative
14. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) PACS · quiet · Evidence leans up · 71% evidence 53.7 out of 100 Growth Capital Valuation Relative
15. [Fresenius Medical Care AG](https://www.sectoralpha.in/us/stocks/fms) FMS · basing · Evidence leans up · 81% evidence 50.7 out of 100 Growth Capital Valuation Relative
16. Chemed Corporation this page CHE · quiet · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue 3.3% · Profit -5.2% · Operating margin change 2.3 points · 83% evidence Capital efficiency 19.7/25 · ROCE 28.2% · Operating margin 13.3% · 76% evidence Valuation 5.0/20 · P/E 22.4× · PEG 2.77 · 65% evidence Relative strength 7.4/20 · Lead over its industry -8.8% · Lead over S&P 500 11% · 1 year 22.8% · 100% evidence · 5 of 12 weeks ahead Exact sum: 17.4 + 19.7 + 5 + 7.4 = 49.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 17. [Guardian Pharmacy Services, Inc.](https://www.sectoralpha.in/us/stocks/grdn) GRDN · quiet · Evidence leans down · 64% evidence 49.3 out of 100 Growth Capital Valuation Relative
18. [Surgery Partners, Inc.](https://www.sectoralpha.in/us/stocks/sgry) SGRY · turning · Evidence leans down · 64% evidence 48.8 out of 100 Growth Capital Valuation Relative
19. [DaVita Inc.](https://www.sectoralpha.in/us/stocks/dva) DVA · turning · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
20. [Astrana Health, Inc.](https://www.sectoralpha.in/us/stocks/asth) ASTH · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
21. [The Pennant Group, Inc.](https://www.sectoralpha.in/us/stocks/pntg) PNTG · turning · Evidence leans down · 81% evidence 43.9 out of 100 Growth Capital Valuation Relative
22. [The Ensign Group, Inc.](https://www.sectoralpha.in/us/stocks/ensg) ENSG · turning · Evidence leans down · 81% evidence 43.0 out of 100 Growth Capital Valuation Relative
23. [agilon health, inc.](https://www.sectoralpha.in/us/stocks/agl) AGL · quiet · Evidence leans down · 64% evidence 41.2 out of 100 Growth Capital Valuation Relative
24. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) OPCH · breaking out · Evidence leans down · 81% evidence 41.0 out of 100 Growth Capital Valuation Relative
25. [Acadia Healthcare Company, Inc.](https://www.sectoralpha.in/us/stocks/achc) ACHC · quiet · Evidence leans down · 71% evidence 37.5 out of 100 Growth Capital Valuation Relative
26. [U.S. Physical Therapy, Inc.](https://www.sectoralpha.in/us/stocks/usph) USPH · leader · Evidence leans down · 81% evidence 36.3 out of 100 Growth Capital Valuation Relative
27. [Sonida Senior Living, Inc.](https://www.sectoralpha.in/us/stocks/snda) SNDA · basing · Evidence leans down · 64% evidence 36.2 out of 100 Growth Capital Valuation Relative
28. [Ardent Health, Inc.](https://www.sectoralpha.in/us/stocks/ardt) ARDT · losing its lead · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [Brookdale Senior Living Inc.](https://www.sectoralpha.in/us/stocks/bkd) BKD · quiet · Most evidence points down · 64% evidence 32.8 out of 100 Growth Capital Valuation Relative
30. [Select Medical Holdings Corporation](https://www.sectoralpha.in/us/stocks/sem) SEM · Too little evidence to rank firmly · 36% evidence 50.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Care Facilities](https://www.sectoralpha.in/us/sectors/medical-care-facilities), all 30 compared on one page. ## Which companies are close to Chemed in size? Chemed is the 9th largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: The Ensign Group, Inc., Universal Health Services, Inc. and PACS Group, Inc. Just below it: Concentra Group Holdings Parent, Inc., LifeStance Health Group, Inc. and Option Care Health, Inc. ### Medical Care Facilities companies close in size

1. [The Ensign Group, Inc.](https://www.sectoralpha.in/us/stocks/ensg) $10.5 billion
2. [Universal Health Services, Inc.](https://www.sectoralpha.in/us/stocks/uhs) $10.4 billion
3. [PACS Group, Inc.](https://www.sectoralpha.in/us/stocks/pacs) $7.4 billion
4. Chemed Corporation $6.9 billion
5. [Concentra Group Holdings Parent, Inc.](https://www.sectoralpha.in/us/stocks/con) $5.1 billion
6. [LifeStance Health Group, Inc.](https://www.sectoralpha.in/us/stocks/lfst) $5.1 billion
7. [Option Care Health, Inc.](https://www.sectoralpha.in/us/stocks/opch) $4.8 billion

[All 38 Medical Care Facilities companies, largest first](https://www.sectoralpha.in/us/sectors/medical-care-facilities#all-companies)

### Companies close in size in other industries

1. [Conagra Brands, Inc.](https://www.sectoralpha.in/us/stocks/cag) $7.1 billion · Packaged Foods
2. [Victory Capital Holdings, Inc.](https://www.sectoralpha.in/us/stocks/vctr) $7 billion · Asset Management
3. Chemed Corporation $7 billion
4. [Crocs, Inc.](https://www.sectoralpha.in/us/stocks/crox) $7 billion · Footwear & Accessories
5. [Abercrombie & Fitch Co.](https://www.sectoralpha.in/us/stocks/anf) $7 billion · Apparel Retail

## What else do people ask about Chemed? ### What were Chemed's latest quarterly results? Chemed Corporation reported revenue of $673 M and net profit of $67.7 M for the Jun 2026 quarter. Revenue rose 8.8% and profit rose 29.0% compared with a year earlier. Earnings per share were $5.13. The operating margin was 13.2%, 2.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Chemed's market cap? Chemed Corporation's market capitalisation is $6.9 B at a stock price of $533.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Chemed performing? Chemed Corporation's share price has been rising for 4 weeks. In its latest quarter, revenue rose 8.8% and profit rose 29.0% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 5 weeks running (as of 3 November 2026). ### Will Chemed's stock price go up? This page does not forecast Chemed Corporation's stock price. What it shows instead: the stock price is $533.65, and it has been rising for 4 weeks. Its P/E of 25.5× is higher than 24% of its own last 5 years (as of 3 November 2026). ### Does Chemed have too much debt? Chemed Corporation has a moderate amount of debt: its debt is 0.46× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Chemed in its business cycle? Chemed Corporation's FY25 operating margin was 13.6%, against a 5-year range of 13.6% to 16.3%: the low end of its own range, which is often where recoveries start. The latest quarter was 13.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Chemed story? The main question: the share price moved +23.7% in a year while yearly earnings per share moved −7.8%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Chemed a stock worth studying right now? What the numbers show: Chemed Corporation's results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 24% of past readings. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.